Book previews

Friday, January 04, 2019

Is Kaposi's Sarcoma responsible for the digestive disorders in Chronic Fatigue Syndrome?

Kaposi Sarcoma Involving the Gastrointestinal Tract

Although gastrointestinal Kaposi sarcoma is usually asymptomatic, hemorrhages from the oral cavity, esophagus, stomach, and large bowel have been reported in this disease., Some patients present with abdominal pain, weight loss, nausea, vomiting, malabsorption, or diarrhea.Further complications of gastrointestinal Kaposi sarcoma can be perforation or obstruction of the bowel.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933764/



This is what oral Kaposi's Sarcoma looks like.




Source: https://doctorspiller.com/kaposis-sarcoma/

Compare it to these crimson crescent lesions in the mouths of Chronic Fatigue Syndrome patients.



"Burke A. Cunha, MD, discovered what he called crimson crescents in the mouths of 80% of his CFS patients. After the word got out, Cunha received calls from other parts of the country. Physicians began telling him that they also were finding the crimson crescents in their patients once they looked for them."

https://www.prohealth.com/library/crimson-crescents-facilitate-chronic-fatigue-syndrome-cfs-diagnosis-11266




Chronic Fatigue Syndrome patients may have undiagnosed internal Kaposi's Sarcoma. Susan Levine found HHV-8, the Kaposi's Sarcoma virus, in half of CFS patients she looked at.

Prevalence in the Cerebrospinal Fluid of the Following Infectious Agents in a Cohort of 12 CFS Subjects
Susan Levine

Published online: 04 Dec 2011


Over the last decade a wide variety of infectious agents has been associated with the chronic fatigue syndrome (CFS) as potential etiologies for this disorder by researchers from all over the world. Many of these agents are neurotrophic and have been linked previously to other diseases involving the central nervous system (CNS). Human herpes virus-6 (HHV-6), especially the B variant, has been found in autopsy specimens of patients who suffered from multiple sclerosis. Because patients with CFS manifest a wide range of symptoms involving the CNS as shown by abnormalities on brain MRIs, SPECT scans of the brain and results of tilt table testing we sought to determine the prevalence of HHV-6, HHV-8, Epstein-Barr virus (EBV), cytomegalovirus (CMV), Mycoplasma species, Chlamydia species, and Coxsackie virus in the spinal fluid of a group of 12 patients with CFS. Although we intended to search mainly for evidence of actively replicating HHV-6, a virus that has been associated by several researchers with this disorder, we found evidence of HHV-8, Chlamydia species, CMV and Coxsackie virus in 6/12 samples. Attempts were made to correlate the clinical presentations of each of these patients, especially the neurological exams and results of objective testing of the CNS, with the particular infectious agent isolated. It was also surprising to obtain such a relatively high yield of infectious agents on cell free specimens of spinal fluid that had not been centrifuged. Future research in spinal fluid analysis, in addition to testing tissue samples by polymerase chain reaction (PCR) and other direct viral isolation techniques will be important in characterizing subpopulations of CFS patients, especially those with involvement of the CNS.

https://www.tandfonline.com/doi/abs/10.1300/J092v09n01_05






HHV-8 is a Kaposi's Sarcoma cancer virus in many AIDS and Chronic Fatigue Syndrome patients and is spread by kissing but the CDC couldn't care less.



http://www.washington.edu/news/2000/11/08/kissing-may-spread-human-herpes-virus-8-the-cause-of-kaposis-sarcoma-among-men/

Company founded by Robert Gallo suggests 65% of gay men are infected with Kaposi's Sarcoma virus.





These two grant requests present a disturbing picture of a virus that could turn the AIDS epidemic paradigm upside down.

DESCRIPTION (provided by applicant): Kaposi's sarcoma herpes virus (KSHV) also known as human herpes virus 8 (HHV-8) causes several cancers including Kaposi's sarcoma, primarily in immune-compromised patients. HHV-8 has been shown to be transmitted sexually, through saliva, and through infected blood and organs to recipients. While a number of serological assays have been devised in the research setting to detect HHV-8 infection, there are no FDA-approved assays. Furthermore, there is no gold standard diagnostic assay for HHV-8 infection and none are of adequate sensitivity and specificity to be used commercially for diagnostic or blood screening purposes. Nevertheless, these assays have revealed that as much as 3 to 5% of US blood donors have been infected with HHV-8, and some high-risk populations such as homosexual men, the HHV-8 prevalence is as high as 65%. Thus, there is a need for a commercial diagnostic to identify HHV-8 infected individuals to prevent further transmission of this virus within thegeneral population and immune-compromised individuals as well as into the general blood supply. The overall goal of this project is to develop a sensitive and specific serological multi-antigen assay for the detection of HHV-8 antibodies that can be usedcommercially to diagnose at-risk patients and identify blood/tissue donors with HHV-8 infection. Epiphany's first-generation HHV-8 enzyme- linked immunosorbent assay diagnostic (ELISA), composed of a single antigen assay and a dual antigen assay, provide gt80% sensitivity and 96% specificity in identifying HHV-8 infected individuals and thus one of the more sensitive diagnostics. However, to be a commercial success, the sensitivity and specificity needs to be improved which we propose by improving the quality and number of capture antigens. In our Phase I grant, we demonstrated the feasibility of our approach by identifying an improved K8.1 capture antigen expressed in a eukaryotic system. To further optimize the assay for commercial use, we will in Aim 1 expand our search for both improved and new capture antigens, then in Aim 2 we will develop a multi-antigen assay. In Aim 3 we will conduct pilot-scale production and beta testing of the diagnostic assay to determine the specificity and sensitivity of the assay by retrospective testing of clinical blood samples. Achieving the goals in this project would generate a commercial HHV-8 diagnostic test which will identify infected patients and donors to reduce transmission risk and to make the blood supply safer.PUBLIC HEALTH RELEVANCE: Infection with the herpes virus HHV-8, only discovered in 1994, may cause several cancers including Kaposi's sarcoma, especially in patients with weak immune systems such as those with HIV. HHV-8 can be transmitted sexually, through saliva, and via blood and organ donations and approximately up to 5% of blood donors in the US have been infected with HHV-8. The project proposes to develop for commercialization a blood test to identify HHV-8 infected individuals thereby providing a diagnosis for infected individuals to understand their risk and modify their behavior as well as make the blood supply much safer for high-risk individuals and blood recipients in general.


https://www.sbir.gov/sbirsearch/detail/389029

Project Summary Abstract

 Kaposi's sarcoma herpes virus KSHV is an oncovirus that causes several cancers including Kaposi's sarcoma KS It is estimated that to of U S blood donors have been infected with KSHV yet in some high risk populations such as homosexual men prevalence is as high as In spite of HAART KS remains the second most common AIDS associated malignancy A third of AIDS KS cases now arise in individuals with relatively high CD cell counts and low HIV viral load A recent study has observed a continuing high prevalence and increased acquisition of KSHV in HIV infected persons on HAART The data clearly indicate that KS is still occurring in HIV infected individuals even in the context of successful HAART In immunosuppressed populations approximately in transplant patients will develop KS The prevalence of KSHV is responsible for the continuing incidence of KS and its associated reduction in life expectancy of HIV individuals Despite its strong disease association particularly in the HIV and immunosuppressed populations there is no FDA approved clinical diagnostic test for KSHV and consequently a significant unmet need remains for a simple cost effective commercially viable KSHV diagnostic kit that would be an essential component of any effort to control virus transmission and monitor serostatus of those already infected The ability to gauge the KSHV serostatus of an HIV individual would help clinicians make appropriate interventional choices to prevent KS onset The overall goal of this project is to develop a serological multi antigen assay for the detection of KSHV antibodies that can be used commercially to diagnose at risk patients and identify blood tissue donors with KSHV infection In prior SBIR Phase I and II work Epiphany developed a single well multi antigenic KSHV enzyme linked immunosorbent assay ELISA called Combo In screening a sera panel containing both KSHV true positives and normal low risk blood donors Combo was the only assay out of other independent ELISAs to detect all consensus KSHV samples with excellent specificity and sensitivity estimated andgt respectively For the next stage of the kit development it is critical to examine Comboandapos s performance against large sera banks of epidemiologically validated KSHV positive and negative controls with relevant confirmatory assays to establish the true effectiveness of the assay A collaborative consortium that merges Epiphany with the biomedical and clinical research capabilities of the University of Miami UofM Miller School of Medicine the Miami Center for AIDS Research CFAR and the labs of Dr Enrique A Mesri CFAR has been created Together Epiphany and Miami CFAR are uniquely equipped to achieve the following Aims In Aim synthetic manufacturing and analytical process development will be implemented followed by pilot production of a set of Combo diagnostic ELISA kits In Aim these kits will be assessed and optimized by screening retrospective clinical blood samples and serologically characterized plasma PMBCs and validated by western blot In Aim large scale kit production will commence Assay stability and validation studies will be performed A larger panel of HIV sera and tissues available to UofM CFAR its cores and transplant centers and national repositories will be massively screened to establish sensitivity and specificity Achieving the goals of this project will establish the clinical and commercial value of Combo ultimately resulting in the first FDA approved clinical diagnostic assay for KSHV Project Narrative Kaposiandapos s sarcoma herpes virus KSHV is an oncovirus that causes several cancers including Kaposiandapos s sarcoma KS especially in patients with weakened immune systems such as those infected with HIV Even in the age of HIV antiretroviral therapy KSHV co infection remains a serious health issue for the HIV positive population and is still the second most common cause of malignancies among AIDS patients Despite its strong disease association particularly in the HIV positive and immunosuppressed populations there is no FDA approved clinical diagnostic test for KSHV and consequently this project seeks to develop a simple cost effective commercially viable KSHV diagnostic assay kit that would be an essential component of any effort to control virus transmission and monitor serostatus of those already infected in order to help clinicians make appropriate interventional choices to prevent KSHV related disease 


https://www.sbir.gov/sbirsearch/detail/1305781

 If you have Amazon Prime or Kindle Unlimited you can immediately begin reading this book that challenges the whole AIDS paradigm.


If you have Amazon Prime or Kindle Unlimited, you can immediately begin reading The Chronic Fatigue Syndrome Epidemic Cover-up and you will soon understand why the facts about the Chronic Fatigue Syndrome epidemic have been hidden from the public for almost four decades.








If you want to know the truth about the Chronic Fatigue Syndrome epidemic, you need to discover the reporting of Neenyah Ostrom.
For a decade, starting in 1988, Ostrom reported on Chronic Fatigue Syndrome for a newspaper called New York Native. What her reporting uncovered about the true nature of the Chronic Fatigue Syndrome epidemic will shock you.
                                                          
In The Chronic Fatigue Syndrome Epidemic Cover-up, Charles Ortleb recounts his newspaper's struggle to get the medical and political establishment to pay attention to Ostrom's pioneering investigative reporting on Chronic Fatigue Syndrome. 
                                                    
By the time you finish Ortleb's stunning memoir, you will understand why the Centers for Disease Control has been unwilling to tell the public the truth about Chronic Fatigue Syndrome. The CDC does not want the public to know that Chronic Fatigue Syndrome is a transmissible illness linked to a virus called HHV-6 that affects every system in the body. They have covered up the illness for so many decades that the neglected virus is totally out of control. Now it is causing a long list of other illnesses and many cancers. 
                                               
Nobody in the world covered the emergence of HHV-6 and its link to Chronic Fatigue Syndrome more than Neenyah Ostrom. Ostrom's decade of reporting on HHV-6 was recently vindicated by this statement from scientists at the University of Wurzburg: "While HHV-6 was long believed to have no negative impact on human health, scientists today increasingly suspect the virus of causing various diseases such as multiple sclerosis or chronic fatigue syndrome. Recent studies even suggest that HHV-6 might play a role in the pathogenesis of several diseases of the central nervous system such as schizophrenia, bipolar disorder, depression or Alzheimer's." 
   
The big question about Neenyah Ostrom and New York Native is this: How many lives would have been saved if the scientific establishment and the mainstream media had paid more attention to Neenyah Ostrom's reporting on HHV-6 and Chronic Fatigue Syndrome in New York Native?
   
One day, if there is any justice in the world, the CDC and the medical establishment will apologize for not paying attention to Neenyah Ostrom's groundbreaking work on Chronic Fatigue Syndrome that Charles Ortleb published in New York Native. That would be a fitting end to one of journalism's greatest David and Goliath stories.





Purchase the book in Canada 

Purchase the book in Mexico

Purchase the book in the United Kingdom

Purchase the book in Germany

Purchase the book in France



These two grant requests present a disturbing picture of a virus that could turn the AIDS epidemic paradigm upside down.

DESCRIPTION (provided by applicant): Kaposi's sarcoma herpes virus (KSHV) also known as human herpes virus 8 (HHV-8) causes several cancers including Kaposi's sarcoma, primarily in immune-compromised patients. HHV-8 has been shown to be transmitted sexually, through saliva, and through infected blood and organs to recipients. While a number of serological assays have been devised in the research setting to detect HHV-8 infection, there are no FDA-approved assays. Furthermore, there is no gold standard diagnostic assay for HHV-8 infection and none are of adequate sensitivity and specificity to be used commercially for diagnostic or blood screening purposes. Nevertheless, these assays have revealed that as much as 3 to 5% of US blood donors have been infected with HHV-8, and some high-risk populations such as homosexual men, the HHV-8 prevalence is as high as 65%. Thus, there is a need for a commercial diagnostic to identify HHV-8 infected individuals to prevent further transmission of this virus within thegeneral population and immune-compromised individuals as well as into the general blood supply. The overall goal of this project is to develop a sensitive and specific serological multi-antigen assay for the detection of HHV-8 antibodies that can be usedcommercially to diagnose at-risk patients and identify blood/tissue donors with HHV-8 infection. Epiphany's first-generation HHV-8 enzyme- linked immunosorbent assay diagnostic (ELISA), composed of a single antigen assay and a dual antigen assay, provide gt80% sensitivity and 96% specificity in identifying HHV-8 infected individuals and thus one of the more sensitive diagnostics. However, to be a commercial success, the sensitivity and specificity needs to be improved which we propose by improving the quality and number of capture antigens. In our Phase I grant, we demonstrated the feasibility of our approach by identifying an improved K8.1 capture antigen expressed in a eukaryotic system. To further optimize the assay for commercial use, we will in Aim 1 expand our search for both improved and new capture antigens, then in Aim 2 we will develop a multi-antigen assay. In Aim 3 we will conduct pilot-scale production and beta testing of the diagnostic assay to determine the specificity and sensitivity of the assay by retrospective testing of clinical blood samples. Achieving the goals in this project would generate a commercial HHV-8 diagnostic test which will identify infected patients and donors to reduce transmission risk and to make the blood supply safer.PUBLIC HEALTH RELEVANCE: Infection with the herpes virus HHV-8, only discovered in 1994, may cause several cancers including Kaposi's sarcoma, especially in patients with weak immune systems such as those with HIV. HHV-8 can be transmitted sexually, through saliva, and via blood and organ donations and approximately up to 5% of blood donors in the US have been infected with HHV-8. The project proposes to develop for commercialization a blood test to identify HHV-8 infected individuals thereby providing a diagnosis for infected individuals to understand their risk and modify their behavior as well as make the blood supply much safer for high-risk individuals and blood recipients in general.


https://www.sbir.gov/sbirsearch/detail/389029

Project Summary Abstract

 Kaposi's sarcoma herpes virus KSHV is an oncovirus that causes several cancers including Kaposi's sarcoma KS It is estimated that to of U S blood donors have been infected with KSHV yet in some high risk populations such as homosexual men prevalence is as high as In spite of HAART KS remains the second most common AIDS associated malignancy A third of AIDS KS cases now arise in individuals with relatively high CD cell counts and low HIV viral load A recent study has observed a continuing high prevalence and increased acquisition of KSHV in HIV infected persons on HAART The data clearly indicate that KS is still occurring in HIV infected individuals even in the context of successful HAART In immunosuppressed populations approximately in transplant patients will develop KS The prevalence of KSHV is responsible for the continuing incidence of KS and its associated reduction in life expectancy of HIV individuals Despite its strong disease association particularly in the HIV and immunosuppressed populations there is no FDA approved clinical diagnostic test for KSHV and consequently a significant unmet need remains for a simple cost effective commercially viable KSHV diagnostic kit that would be an essential component of any effort to control virus transmission and monitor serostatus of those already infected The ability to gauge the KSHV serostatus of an HIV individual would help clinicians make appropriate interventional choices to prevent KS onset The overall goal of this project is to develop a serological multi antigen assay for the detection of KSHV antibodies that can be used commercially to diagnose at risk patients and identify blood tissue donors with KSHV infection In prior SBIR Phase I and II work Epiphany developed a single well multi antigenic KSHV enzyme linked immunosorbent assay ELISA called Combo In screening a sera panel containing both KSHV true positives and normal low risk blood donors Combo was the only assay out of other independent ELISAs to detect all consensus KSHV samples with excellent specificity and sensitivity estimated andgt respectively For the next stage of the kit development it is critical to examine Comboandapos s performance against large sera banks of epidemiologically validated KSHV positive and negative controls with relevant confirmatory assays to establish the true effectiveness of the assay A collaborative consortium that merges Epiphany with the biomedical and clinical research capabilities of the University of Miami UofM Miller School of Medicine the Miami Center for AIDS Research CFAR and the labs of Dr Enrique A Mesri CFAR has been created Together Epiphany and Miami CFAR are uniquely equipped to achieve the following Aims In Aim synthetic manufacturing and analytical process development will be implemented followed by pilot production of a set of Combo diagnostic ELISA kits In Aim these kits will be assessed and optimized by screening retrospective clinical blood samples and serologically characterized plasma PMBCs and validated by western blot In Aim large scale kit production will commence Assay stability and validation studies will be performed A larger panel of HIV sera and tissues available to UofM CFAR its cores and transplant centers and national repositories will be massively screened to establish sensitivity and specificity Achieving the goals of this project will establish the clinical and commercial value of Combo ultimately resulting in the first FDA approved clinical diagnostic assay for KSHV Project Narrative Kaposiandapos s sarcoma herpes virus KSHV is an oncovirus that causes several cancers including Kaposiandapos s sarcoma KS especially in patients with weakened immune systems such as those infected with HIV Even in the age of HIV antiretroviral therapy KSHV co infection remains a serious health issue for the HIV positive population and is still the second most common cause of malignancies among AIDS patients Despite its strong disease association particularly in the HIV positive and immunosuppressed populations there is no FDA approved clinical diagnostic test for KSHV and consequently this project seeks to develop a simple cost effective commercially viable KSHV diagnostic assay kit that would be an essential component of any effort to control virus transmission and monitor serostatus of those already infected in order to help clinicians make appropriate interventional choices to prevent KSHV related disease 


https://www.sbir.gov/sbirsearch/detail/1305781

 If you have Amazon Prime or Kindle Unlimited you can immediately begin reading this book that challenges the whole AIDS paradigm.


If you have Amazon Prime or Kindle Unlimited, you can immediately begin reading The Chronic Fatigue Syndrome Epidemic Cover-up and you will soon understand why the facts about the Chronic Fatigue Syndrome epidemic have been hidden from the public for almost four decades.








If you want to know the truth about the Chronic Fatigue Syndrome epidemic, you need to discover the reporting of Neenyah Ostrom.
For a decade, starting in 1988, Ostrom reported on Chronic Fatigue Syndrome for a newspaper called New York Native. What her reporting uncovered about the true nature of the Chronic Fatigue Syndrome epidemic will shock you.
                                                          
In The Chronic Fatigue Syndrome Epidemic Cover-up, Charles Ortleb recounts his newspaper's struggle to get the medical and political establishment to pay attention to Ostrom's pioneering investigative reporting on Chronic Fatigue Syndrome. 
                                                    
By the time you finish Ortleb's stunning memoir, you will understand why the Centers for Disease Control has been unwilling to tell the public the truth about Chronic Fatigue Syndrome. The CDC does not want the public to know that Chronic Fatigue Syndrome is a transmissible illness linked to a virus called HHV-6 that affects every system in the body. They have covered up the illness for so many decades that the neglected virus is totally out of control. Now it is causing a long list of other illnesses and many cancers. 
                                               
Nobody in the world covered the emergence of HHV-6 and its link to Chronic Fatigue Syndrome more than Neenyah Ostrom. Ostrom's decade of reporting on HHV-6 was recently vindicated by this statement from scientists at the University of Wurzburg: "While HHV-6 was long believed to have no negative impact on human health, scientists today increasingly suspect the virus of causing various diseases such as multiple sclerosis or chronic fatigue syndrome. Recent studies even suggest that HHV-6 might play a role in the pathogenesis of several diseases of the central nervous system such as schizophrenia, bipolar disorder, depression or Alzheimer's." 
   
The big question about Neenyah Ostrom and New York Native is this: How many lives would have been saved if the scientific establishment and the mainstream media had paid more attention to Neenyah Ostrom's reporting on HHV-6 and Chronic Fatigue Syndrome in New York Native?
   
One day, if there is any justice in the world, the CDC and the medical establishment will apologize for not paying attention to Neenyah Ostrom's groundbreaking work on Chronic Fatigue Syndrome that Charles Ortleb published in New York Native. That would be a fitting end to one of journalism's greatest David and Goliath stories.















Purchase the book in the Netherlands

Purchase the book in Spain

Purchase the book in Australia

Purchase the book in Japan

Purchase the book in India











A Chronic Fatigue Syndrome bestseller discusses the issue of Kaposi's Sarcoma in Chronic Fatigue Syndrome patients





Excerpted from The Chronic Fatigue Syndrome Epidemic Cover-up, a bestseller on Amazon.

     Neenyah Ostrom began one of my favorite series of articles in the same issue. Titled “The Color Purple,” Ostrom reported, “Burke Cunha, M.D. who is chief of infectious disease at Winthrop-University Hospital (Mineola, Long Island), has described what he calls ‘crimson crescents’ that appear in the throats of more than 80 percent of chronic fatigue syndrome (CFS) patients. Cunha describes the crescents not only as ‘crimson,’ but ‘purplish.’ The reddish-purplish regions found in CFS patients’ throats sounded quite similar to KS (Kaposi’s sarcoma) in the throat, commented an ‘AIDS’ doctor [who wished to remain anonymous] to whom they were described. Is it possible that the crimson crescents observed in the throats of CFS patients are actually a type of KS?”      Ostrom raised the possibility that the lesions in the throats of CFS patients connected them to the theory that Florida researchers held about KS being the unrecognized but unifying central pathological event AIDS. As I previously reported, the Florida team, headed by Dr. George Hensley, had turned the AIDS paradigm upside down, by finding KS in nearly 100% of AIDS patients, when they explored the internal organs closely during autopsies of AIDS patients. Their fascinating work suggested that KS preceded AIDS and caused more of the immune problem in AIDS than previously thought.
285

     Basically, Ostrom was asking if the KS-like lesions, in the tonsils of [CFS]patients, were an indication that some kind of unrecognized indolent KS was present internally, something that physicians would not even be thinking about because of the conceptual wall that socially hostile epidemiology had built between AIDS and chronic fatigue syndrome. And the CFS patients were not particularly interested in finding out if they shared KS with AIDS patients.

    Ostrom went even further, in the July 20 issue, and speculated that the dramatic digestive problems in chronic fatigue syndrome were actually the result of the unrecognized chronic or slowly progressive KS in the CFS patients’ digestive tracts. Ostrom noted that Dr. Carol Jessop, who was talking to a group of patients at a chronic fatigue syndrome conference, said, “Almost all patients would say to me, ‘I was totally well until I got this [chronic fatigue syndrome],’ and yet, when I took their past medical histories, I found it wasn’t quite true. Now these aren’t disastrous problems. In fact, if they had gone to their physicians for any of these problems such as irritable bowel, diarrhea and constipation, abdominal cramping, bloating, flatulence, chronic constipation, heartburn, etc., their physician would probably just say, ‘Oh, take this’ and that would be it. So we as physicians didn’t relate to our patients that this was a problem, so they considered themselves to be totally healthy. Yet, if you look at the numbers, 89 percent of the [chronic fatigue syndrome] patients had irritable bowel syndrome, diarrhea alternating with constipation, and abdominal cramping pain episodically. Another 80 percent complained of constant gas, bloating and flatulence. It’s amazing that we can all meet in this room together.”       Ostrom wondered if “Jessop may have uncovered a fallacy in the prevailing wisdom of chronic fatigue syndrome: that it begins as a respiratory, flu-like illness. Instead, as she points out, it may be a digestive tract disturbance. Jessop’s statistic—that more than 80 percent of CFS patients complain of irritable bowel syndrome, abdominal pain, gas, bloating, etc.—corresponds to the more than 80 percent of CFS patients who exhibit a red-to-purplish crescent-shaped lesion in their throats. (Helot, Paul, in the New York Times Long Island edition, January 14, 1992) . . . What if the digestive problems described by the CFS patients are actually caused by KS in the gastrointestinal tract? According to the AIDS Treatment News, ‘The most common HIV-related causes of gastric symptoms include KS, lymphoma, and CMV [cytomegalovirus].’ And while KS is unusual in the esophagus, it
286

‘may occasionally be found there.’ KS also can cause colitis and diarrhea . . . in people with AIDS.” Ostrom noted, “Gastrointestinal symptoms, it is realized in retrospect, were among the first signs of the ‘AIDS’ epidemic; and, it now seems, were also among the first symptoms seen in the CFS epidemic. That observation raises what should be a relatively simple question to answer: Are the gastrointestinal symptoms in both patient populations caused, in part, by undetected KS?”


Excerpted from The Chronic Fatigue Syndrome Epidemic Cover-up, a bestseller on Amazon.



You think Elizabeth Warren has problems.


Texas has the biggest population of wild hogs. Is that why they have the most cases of Acute Flaccid Myelitis? Are the wild hogs sick?



https://www.wideopenspaces.com/top-10-states-to-hunt-hogs-in-the-us/

Wild boars as sources for infectious diseases in livestock and humans
Wild boars (Sus scrofa) are indigenous in many countries in the world. These free-living swine are known reservoirs for a number of viruses, bacteria and parasites that are transmissible to domestic animals and humans. Changes of human habitation to suburban areas, increased use of lands for agricultural purposes, increased hunting activities and consumption of wild boar meat have increased the chances of exposure of wild boars to domestic animals and humans. Wild boars can act as reservoirs for many important infectious diseases in domestic animals, such as classical swine fever, brucellosis and trichinellosis, and in humans, diseases such as hepatitis E, tuberculosis, leptospirosis and trichinellosis. For examples, wild boars are reservoirs for hepatitis E virus, and cluster cases of hepatitis E have been reported in Japan of humans who consumed wild boar meat. In Canada, an outbreak of trichinellosis was linked to the consumption of wild boar meat. The incidence of tuberculosis owing to Mycobacterium bovis has increased in wild boars, thus posing a potential concern for infections in livestock and humans. It has also been documented that six hunters contracted Brucella suis infections from wild swine in Florida. This article discusses the prevalence.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865094/

Could HHV-6 from sick pigs be infecting victims of Acute Flaccid Myelitis?



Blog Archive

Popular Posts in the Last 30 Days

You can support us by listening to these songs by Charles Ortleb on Spotify.

cfs book scrib promo

Previous HHV-6 University Reports

ad for cfs book

Audible CFS book

Closing Argument Audible

African Swine Fever Novel Audible

Stonewall Audible